TRENTON, N.J.--(BUSINESS WIRE)--BioNJ, the trade association for New Jersey’s biotechnology community, announced today that Christopher P. Austin, M.D., Director, National Center for Advancing Translational Sciences at the National Institutes for Health (NIH) and Graham R. Brazier, Vice President, Business Development, Bristol-Myers Squibb Company will serve as the Keynote Speakers at BioP, BioNJ’s 4th Annual International BioPartnering Conference.
Working from the theme, Partnering: A Path to Patients...Moving Innovation Forward, BioP will be held on Monday, June 17, 2013, at The Westin Princeton at Forrestal Village. BioNJ’s International BioPartnering Conference is expected to attract senior life science executives from global biotech and pharmaceutical companies, the funding community and entrepreneurs from throughout the Eastern U.S., Europe and Asia.
The conference is New Jersey's only biopartnering meeting, giving attendees a unique opportunity to network with industry executives seeking business opportunities, build relationships, discuss possible collaborations and forge partnerships in the Medicine Chest of the World.
In addition to the Keynote Speakers, the conference will focus on networking, partnering sessions, company presentations and an important plenary panel discussion.
The conference is being sponsored by Bristol-Myers Squibb Company, EisnerAmper, Janssen Pharmaceutical Companies of Johnson & Johnson, Merck & Company, Inc. and Sanofi.
Translational Innovation in Medicine
Dr. Austin will provide the Luncheon Keynote Address, discussing Catalyzing Translational Innovation in Medicine for the 21st Century.
Dr. Austin was named Director of the National Center for Advancing Translational Sciences (NCATS) in 2012 where he is applying his experience in nearly every stage of the research pipeline to build on the Center’s momentum in finding innovative ways to reduce, remove or bypass regulatory bottlenecks and speed the delivery of new drugs, diagnostics and medical devices to patients.
The BMS Perspective
As Vice President of Business Development at Bristol-Myers Squibb, Mr. Brazier will speak on Partnering: A Perspective from BMS.
Joining Bristol-Myers Squibb in 2002, Mr. Brazier has transactional responsibility for the full array of collaborations covering research, clinical and commercial stage assets across BMS’ global pharmaceutical business. He is also responsible for Japan Partnering activities.
During his career, Mr. Brazier has successfully led and overseen numerous transaction teams involved in company acquisitions, co-development and co-promotion deals, compound in and out licensing, product disposals, research collaborations, patents licenses and other strategic transactions.
High-Powered Plenary Session
BioP will also feature a unique plenary session in the morning, Points along the Path to Patients: How to Monetize and Expedite Innovations in Research, that will examine the financial steps that a company needs to take to move a product from discovery, to clinical trials, regulatory approval and finally marketing from the perspectives of university and hospital research scientists, a venture capitalist and a company president.
The panel will include: Todd C. Brady, M.D., Ph.D., Entrepreneur in Residence, Domain Associates; Kenneth J. Breslauer, M. Phil., Ph.D., Linus C. Pauling Professor, Dean of Life Sciences, Vice President, Health Science Partnerships, Rutgers, The State University of New Jersey (Tentative); Stephen K. Burley, M.D., D. Phil., Director of the Center for Integrative Proteomics Research, Distinguished Professor of Chemistry and Chemical Biology Member, Cancer Institute of New Jersey; Gary L. Olson, Ph.D., President and CEO; Provid Pharmaceuticals Inc.; and Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chairman and Executive Administrative Director, John Theurer Cancer Center, Hackensack University Medical Center,
“Biotechnology in New Jersey continues to thrive, and bringing companies together from throughout New Jersey and other regions to network, establish collaborations, partnerships and other close business relationships is one of BioNJ’s key roles in helping to maintain the industry’s momentum,” said President and CEO Debbie Hart. “We are grateful to Dr. Austin, Mr. Brazier and other participants for sharing their thoughts on the current and future landscape for collaborations and partnerships within our industry.”
To register and for additional information, please visit http://www.bionj.org/biop2013/home-2.
About BioNJ
With 300 members, BioNJ is singularly focused on advancing the growth and prosperity of New Jersey’s biotechnology cluster through advocacy initiatives directed at State and federal public policy issues and networking and educational programs that bring the community together. Founded in 1994 by New Jersey industry CEOs, BioNJ serves as the voice of biotechnology companies located in New Jersey, seeks to promote their economic growth and development and works to encourage new and established companies from around the world to locate to New Jersey. BioNJ represents companies engaged in biopharmaceutical, biomedical, bioagricultural and bioremedial endeavors. To learn more about BioNJ and the International BioPartnering Conference, please visit www.BioNJ.org.
